[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625657":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":45,"studyPopulation":38,"armGroups":46,"interventions":53,"overallOfficials":58,"centralContacts":65,"locations":70,"responsibleParty":87,"collaborators":89,"id":93,"slug":38,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":38,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":38,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":72,"whyStopped":38,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Changhai Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":38},[9,13,15,17,19],{"measure":10,"description":11,"timeFrame":12},"Dose-limiting toxicity (DLT)","Safety","42 days of first infusion",{"measure":14,"description":11,"timeFrame":12},"Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE)",{"measure":16,"description":11,"timeFrame":12},"Number of participants with abnormal clinical laboratory parameters reported as TEAE",{"measure":18,"description":11,"timeFrame":12},"Number of participants with abnormal vital signs reported as TEAE",{"measure":20,"description":11,"timeFrame":12},"Number of participants with change from baseline in QT\u002FQTc interval in electrocardiogram",[22,25,27,30,32,35],{"measure":23,"description":24,"timeFrame":12},"Objective response rate (ORR)","Efficacy",{"measure":26,"description":24,"timeFrame":12},"Disease control rate (DCR)",{"measure":28,"description":24,"timeFrame":29},"Progression-free survival (PFS)","6 months",{"measure":31,"description":24,"timeFrame":29},"Overall survival (OS)",{"measure":33,"description":34,"timeFrame":12},"Patient-reported quality of life (QoL)","Measured by the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (EORTC QLQ-C30)",{"measure":36,"description":37,"timeFrame":12},"Patient-generated subjective global assessment (PG-SGA)","Nutritional status measurement with a medical history section assessed by patients and a physical assessment section assessed by medical staff",null,{"allocation":40,"interventionModel":41,"interventionModelDescription":38,"primaryPurpose":42,"observationalModel":38,"timePerspective":38,"maskingInfo":43},"NA","SINGLE_GROUP","TREATMENT",{"masking":44,"maskingDescription":38,"whoMasked":38},"NONE","A fixed-dose study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-003) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.",[47],{"label":48,"type":49,"description":50,"interventionNames":51},"CL-NK-003","EXPERIMENTAL","Fixed-dose for at least 6 patients",[52],"Biological: CL-NK-003",[54],{"type":55,"name":48,"description":56,"armGroupLabels":57,"otherNames":38},"BIOLOGICAL","Fixed-dose (3 × 10\\^9 cells)",[48],[59,62],{"name":60,"affiliation":5,"role":61},"Zhuan Liao","PRINCIPAL_INVESTIGATOR",{"name":63,"affiliation":64,"role":61},"Xuetao Cao","National Key Laboratory of Immunity & Inflammation",[66],{"name":63,"role":67,"phone":68,"phoneExt":38,"email":69},"CONTACT","+86-13124828854","caoxt@immunol.org",[71],{"facility":5,"status":72,"city":73,"state":38,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"RECRUITING","Shanghai","200433","China","CN",{"type":78,"coordinates":79},"Point",[80,81],121.45806,31.22222,{"lat":81,"lon":80},[84],{"name":85,"role":67,"phone":68,"phoneExt":38,"email":86},"Yanfang Liu","liuyanfang00215@163.com",{"type":61,"investigatorFullName":60,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Prof.",[90],{"name":91,"class":92},"National Key Laboratory of Immunity and Inflammation","UNKNOWN","100625657",false,"NCT07425483","CAR-NK Cells (CL-NK-003) in Pancreatic Cancer","A Clinical Study of CAR-NK Cells (CL-NK-003) in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Aged 18-75 years;2. Locally advanced, metastatic, or recurrent pancreatic cancer, with immunohistochemical detection of eGR1 (membrane positive tumor cell rate \\>40% and expression intensity ≥2+), who have failed, been intolerant to or reject standard treatment;3. At least 1 measurable lesion according to RECIST 1.1;4. Have not received anti-tumor treatment for at least 4 weeks;5. ECOG performance status of 0-2;6. Estimated life expectancy more than 12 weeks;7. Hematology: neutrophils ≥ 1.5×10\\^9\u002FL, lymphocytes ≥ 0.8×10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, and platelets ≥ 75 × 10\\^9\u002FL;8. Blood biochemistry: total bilirubin ≤ 2×ULN, alanine aminotransferase ≤ 3×ULN, aspartate aminotransferase ≤ 3×ULN, and creatinine clearance ≥ LLN (Cockcroft-Gault formula);9. Volunteer to participate in this clinical study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Evidence of central nervous system involvement;2. Have received adoptive cell therapy;3. Patients with any uncontrolled active infection, including but not limited to: HBV, HCV, HIV, or treponema pallidum serology positive;4. Vaccinated with a live attenuated vaccine within 3 months;5. History of immunodeficiency;6. Active autoimmune disease;7. Regular use of systemic corticosteroids within 2 weeks prior to screening at a dose exceeding prednisone 10 mg\u002Fday (or equivalent) on any day; 8. Have severe conditions, including but not limited to: (1) severe respiratory diseases; (2) severe cardiovascular diseases (previous history of CABG\u002FPCI; myocardial infarction\u002Funstable angina pectoris, congestive heart failure of NYHA III-IV, left ventricular ejection fraction \\\u003C 50%, or poorly controlled hypertension within 6 months; QTc interval \\> 480ms, long or short QT syndrome; previous history of ventrical arrhythmia, or ventrical arrhythmia under anti-arrhythmic drugs\u002FICD); (3) poorly controlled diabetes and other metabolic diseases; (4) severe gastrointestinal diseases (severe gastrointestinal bleeding, severe diarrhea of CTCAE ≥ 2, or severe gastrointestinal obstruction needing intervention);9. Possible severe adverse events, allergy or other contraindications to drugs or its component under study;10. Pregnant or lactating women;11. History of neurological or psychological disorders;12. Not suitable to participate this clinical study judged by the investigator.","ALL","18 Years","75 Years",{"count":103,"type":104},9,"ESTIMATED","INTERVENTIONAL",[107],"PHASE1","This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.",[110],"Pancreatic Cancer",[112,113],"pancreatic cancer","CAR-NK","2026-02-13",{"date":116,"type":117},"2026-02-23","ACTUAL",{"date":119,"type":117},"2026-02-12",{"date":121,"type":104},"2028-12",{"name":5,"class":6},1]